Formulation Development
FORMULATION DEVELOPMENT WHITE PAPERS & ARTICLES
-
![Smart Manufacturing facility-GettyImages-1938951579]( "Safety First: Considerations When Formulating High Potency Compounds")
Safety First: Considerations When Formulating High Potency CompoundsDeveloping highly potent APIs comes with unique challenges. Explore strategies for managing risk, protecting personnel, and advancing programs with confidence.
-
![GettyImages-1585548490-modular-facility-laboratory-drug-development]( "Insights Into Evionnaz's new R&D Center")
Insights Into Evionnaz's new R&D CenterPharmaceutical innovation depends on speed and smarter decisions. Discover how advanced R&D technologies and real-time insights are helping accelerate development.
-
![Three Success Factors To Accelerate Your Program To Clinical Trial_Siegfried]( "Three Success Factors To Accelerate Your Program To Clinical Trial")
Three Success Factors To Accelerate Your Program To Clinical TrialAccelerating clinical timelines starts with a strong foundation. Discover how smart development strategies can reduce risk, conserve resources, and support future scale-up.
-
![Questions That Will Accelerate The Speed Of Your Program To Clinical_Siegfried]( "Questions That Will Accelerate The Speed Of Your Program To Clinical")
Questions That Will Accelerate The Speed Of Your Program To ClinicalThe right early-stage strategy can prevent costly delays later. Explore key considerations for advancing programs to the clinic with confidence.
-
![pharmaceutical-manufacturing-GettyImages-2196233593]( "Navigating Shifts In Supply Chain And Manufacturing")
Navigating Shifts In Supply Chain And ManufacturingAs development demands grow, success depends on flexibility and resilience. Learn how manufacturers are adapting to meet new challenges.
FORMULATION DEVELOPMENT APPLICATIONS & STUDIES
-
![GettyImages-1167352850-antibody-green]( "Streamline Antibody Analysis For Faster Protein Characterization")
Streamline Antibody Analysis For Faster Protein CharacterizationStrengthen your antibody characterization. Explore approaches for improving sizing accuracy, resolving heterogeneity, and generating reproducible data across demanding biopharmaceutical workflows.
-
![Cell and Gene pharma manufacturing bioprocess GettyImages-1166528646]( "Don't Intensify Blindly: Preventing Fouling And Restoring Performance With Targeted Cleaning Of Protein A Resins")
Don't Intensify Blindly: Preventing Fouling And Restoring Performance With Targeted Cleaning Of Protein A ResinsProtein A chromatography intensification can increase productivity, but it may also affect process robustness. Explore key tradeoffs, operational challenges, and practical considerations.
-
![GettyImages-899692950-cleanroom-microscopes-scientists-analyze]( "Detect Low-Abundance GLP-1 Impurities With Greater Sensitivity")
Detect Low-Abundance GLP-1 Impurities With Greater SensitivityLow-level impurities can be difficult to resolve using conventional approaches. Discover how a Charged Surface 2.3 µm superficially porous Phenyl-Hexyl column enhances reversed-phase LC-MS analysis.
-
![GettyImages-1309780330-HPLC-lab-scientist-chromatography]( "Differentiate Challenging Site-Specific Isomeric Amino Acids")
Differentiate Challenging Site-Specific Isomeric Amino AcidsLearn how high-resolution ion mobility, pre-IMS fragmentation, and product ion analysis can resolve difficult peptide isomers and localize structural differences, supporting confident characterization.
-
![Female researcher analyzing scientific samples-GettyImages-2231025177]( "Increase Throughput For Intact Mass Confirmation And Impurity Screening")
Increase Throughput For Intact Mass Confirmation And Impurity ScreeningAccelerate intact mass analysis of GLP-1 analogues with automated purity calculations, sub-ppm mass accuracy, and impurity detection for consistent results in under one minute per sample.
FORMULATION DEVELOPMENT PRODUCTS & SERVICES
Measure heat flow, weight loss, dimension change, or mechanical properties as a function of temperature.
Optimize your cell line strategy for better viral vector production.
Synthetic oligonucleotide therapeutics, such as antisense oligonucleotides (ASOs) and small interfering RNAs (si-RNAs), require thorough analysis to establish purity and quality.
The journey of a GLP-1 receptor agonist (GLP-1 RA) molecule is complex.
Rules-Based Fragment Prediction for Mass Spectrometry
ACD/MS Fragmenter helps you predict mass spectral fragmentation in seconds. Have more confidence in your compound IDs, learn about fragmentation mechanisms, and publish your results easily.
It’s as simple as this:
- Draw your compound
- Select the ionization polarity and fragmentation options
- View its fragmentation tree
MabSelect™ VL resin — protein L resin for affinity capture of antibody Fabs, bispecifics, and other variants containing a kappa light chain.
Our solutions have been specified in the testing process for the top two GLP-1 manufacturers
As part of Stevanato Group’s commitment to R&D, our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs. Stevanato Group relies on a multi-disciplinary team of highly skilled professionals, including, scientists, engineers, pharmaceutical chemists and biotechnologists. Their knowledge and experience covers a range of specialized areas including container closure systems and drug-delivery devices.
FORMULATION DEVELOPMENT SOLUTIONS
- Where Expertise Meets Simplicity: BD PartnerPath™ Program
- Leading The Way In Rapid Quantitation Of Host Cell DNA
- Curia R&D Pipeline Overview
- Small Molecule Drug Substance
- Controlled Substances
- High Potency API Development And Manufacturing
- Developing Palatable, Age Appropriate Drug Products
- Your End-To-End CDMO Partner
- Resin Offering High Productivity And Robust Processes
- R&D And Analytical Services
PHARMACEUTICAL AND FORMULATION DEVELOPMENT NEWS
- Future Fields Closes Oversubscribed $8M Series A to Turn Flies Into Bioreactors That Address Undruggable Diseases
- Germfree Announces New Chief Financial Officer And Chief Commercial Officer
- Siegfried Delivers Profitable Growth And Confirms Outlook
- Siegfried Strengthens Manufacturing Network With New Large-Scale Drug Substance Facility In Minden
- Siegfried Successfully Places Senior Bonds Of CHF 200 Million
- Siegfried Included In Dow Jones Best-In-Class Europe Index
- Siegfried DINAMIQS Receives Swissmedic License For Viral Vector Manufacturing
- Siegfried Obtains Antitrust Clearance For Acquisition Of Three Drug Substances Sites In The US And Australia
- Siegfried Shareholders Approve All Proposals At Annual General Meeting 2026
- Siegfried Delivers Strong Profitability And Continued Growth